Oral anticoagulation therapy (OAC) is presented in approximately 10% of patient treated with coronary angioplasty.
Treat ment with OAC means logistic problem for PCI and its combination with dual antiplatelet therapy increases substantially
bleeding risk. Empirical approach to this therapy is progressively substituted with more reliable data from
randomized clinical trials.